美銀美林:領軍企業推動全球新一代療法創新 予和鉑醫藥(2142.HK)15.6港元目標價
格隆匯1月15日丨美銀美林發研報指,和鉑醫藥(2142.HK)是一家全球臨牀階段生物製藥公司,具有三個行業領先的專有抗體研發平台(H2L2(全人源抗體藥物),HCAb(全人源重鏈抗體)和HBICE(專有BsAb分子)),均可用於新一代療法的研發。公司在臨牀階段有三種核心產品,其中,Batoclimab是目前中國首個通過皮下注射的FcRn抑制劑,Tanfanercept具有先發優勢,HBM4003也是第一個處在臨牀開發階段的全人源重鏈抗體。根據該行DCF模型的合理推測,公司市值為120億港元,對應的目標價為15.6港元。和鉑醫藥(2142.HK)繼昨日收漲11.89%後,今日盤中再度漲超4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.